novo nordisk news - Search News

Novo Nordisk, Evotec

The Motley Fool · 1d

Forget Novo Nordisk, Buy This Magnificent Dividend Stock Instead

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium investing solutions, free guidance and market analysis on Fool.com, top-rated podcasts, and non-profit The Motley Fool Foundation.

Evotec and Novo Nordisk in technology development partnership

German drug and development company Evotec has entered into a technology development partnership with Novo Nordisk to support clinical and commercial manufacturing of stem cell-based therapies, the company said on Thursday.

Business Insider · 1d

EQS-News: Evotec and Novo Nordisk enter into technology development partnership to support next-generation cell therapies

Miscellaneous 26.09.2024 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. Novo Nordisk will provide funding for technology development activities at Evotec to support clinical and commercial manufacturing of stem cell-based therapies Hamburg,

Hosted on MSN · 1d

Novo Nordisk And Evotec Collaborate On Stem Cell-Based Therapy Development

Ozempic could lower risk of opioid overdoses, says new study

CNBC on MSN · 2d

Novo Nordisk's diabetes drug Ozempic may lower the risk of opioid overdoses, study says

The results suggest Ozempic could potentially become a new alternative treatment for opioid use disorder, which could help address the ongoing opioid epidemic.

Study: Ozempic might lower risk of opioid overdose

In a finding that suggests Ozempic and Wegovy have powers that extend beyond weight loss, a new study finds the medications might also lower people's risk of opioid overdose.

Axios Vitals on MSN · 1d

Ozempic linked to drop in opioid overdose risk: study

The active ingredient in the popular diabetes and obesity drugs Ozempic and Wegovy could be linked to a drop in opioid overdoses, a study published in JAMA Network Open found. Why it matters: It's the latest evidence that buzzy drugs known as GLP-1s could be used to address psychiatric disorders,

2h

Novo Nordisk Just Committed More Than $1.1 Billion to Make the Next Ozempic, but Is the Stock a Buy?

In mid-September, Novo Nordisk inked a pair of deals worth a total of more than $1.1 billion in research and development (R&D ...

Lilly Is Not ‘Feeling the Bern’ on Drug Prices Like Novo: Why the Double Standard?

Sen. Bernie Sanders’ aggressive targeting of Danish drugmaker Novo Nordisk’s Ozempic and Wegovy pricing, and not Eli Lilly’s ...

19h

RFK Jr. bashes Ozempic buzz and Novo Nordisk profits

Robert F. Kennedy Jr. criticized Ozempic and Danish pharmaceutical company Novo Nordisk, arguing that fixing the food supply ...

2d

Senators press Novo Nordisk CEO on why Ozempic and Wegovy cost less abroad

Weight-loss drugs sell in Europe for a fraction of what they cost in the United States, a pattern that is typical for ...

2d

Why does Ozempic cost so much? Senators grilled Novo Nordisk CEO for answers.

Novo Nordisk CEO grilled over company's pricing for the diabetes drug Ozempic and the weight-loss drug Wegovy.

6h

Novo Nordisk (0QIU) Receives a Buy from J.P. Morgan

In a report released today, Richard Vosser from J.P. Morgan maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a ...

Novo Nordisk scolded by UK drug marketing watchdog over sponsorship of weight loss services

Novo Nordisk has earnt yet another dressing down from the PMCPA. The U.K. | Novo Nordisk has earnt yet another dressing down ...

2don MSN

Senate panel questions Novo Nordisk CEO over decision to discontinue this popular insulin

Novo Nordisk CEO explains decision to discontinue the long-acting insulin Levemir. He blamed pharmacy managers and health ...

2d

Novo Nordisk CEO Grilled by Congress Over Price of Ozempic

During a tense hearing before a Senate committee on Tuesday, Novo Nordisk CEO Lars Fruergaard Jørgensen faced tough questions ...

4h

Novo Nordisk’s Wegovy-Fueled Gains Fading as Analyst Doubts Grow

The obesity-drug hype that fueled huge gains in Novo Nordisk A/S looks to be running out of steam.Most Read from ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results